← Back to Search

Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg for High Blood Pressure (GMRx2_PCT Trial)

Phase 3
Recruiting
Led By Anthony Rodgers, Professor
Research Sponsored by George Medicines PTY Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 days
Treatment 3 months
Follow Up 1 months
Awards & highlights

GMRx2_PCT Trial Summary

This trial will test how well a combination of three low-dose drugs works to control blood pressure, compared to a placebo.

Eligible Conditions
  • High Blood Pressure

GMRx2_PCT Trial Timeline

Screening ~ 3 days
Treatment ~ 3 months
Follow Up ~1 months
This trial's timeline: 3 days for screening, 3 months for treatment, and 1 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Difference in change in home SBP from baseline to Week 4
Secondary outcome measures
Difference in change in clinic seated mean DBP from baseline to Week 4
Difference in change in clinic seated mean SBP from baseline to Week 4
Difference in change in home seated mean DBP from baseline to Week 4
+6 more
Other outcome measures
Safety Outcomes

GMRx2_PCT Trial Design

3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Triple ¼ (GMRx2)Experimental Treatment1 Intervention
Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg
Group II: Triple ½ (GMRx2)Active Control1 Intervention
Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
Group III: PlaceboPlacebo Group1 Intervention
Placebo

Find a Location

Logistics

Other reimbursement is provided

Other forms of reimbursement are provided for this trial.

Who is running the clinical trial?

George Medicines PTY LimitedLead Sponsor
2 Previous Clinical Trials
1,719 Total Patients Enrolled
Anthony Rodgers, ProfessorPrincipal InvestigatorThe George Institute
1 Previous Clinical Trials
1,385 Total Patients Enrolled
~64 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top